How a Supreme Court fight over fish oil could raise your prescription drug costs

The Supreme Court is set to hear Hikma v. Amarin, a patent dispute over fish oil-based drugs that could increase prescription drug costs for patients and disrupt generic drug company operations. The case centers on whether Amarin's patent for Vascepa (a fish oil drug) was invalidated by prior art, which could affect how generic manufacturers navigate patent challenges.